TEL-AVIV, Israel, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Tarsius Pharma, a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, is pleased to announce that management will participate in the Piper Sandler 32^nd Annual Healthcare Conference, being held virtually on November 30^th to December 3^rd, 2020. In advance of the virtual conference and investor meetings, a pre-recorded corporate update given by Dr. Daphne Haim-Langford, CEO and founder of Tarsius Pharma, will be made available, on Monday, November 23^rd, in the News & Events section of the company's website. Replay of the webcast will be available for 90 days following the event. 

"We are excited to actively contribute to this prestigious conference and are looking forward to network and exchange with peers and stakeholders," said Dr. Haim-Langford. Tarsius will be participating in 1X1 meetings between November 30^th and December 3^rd, additional meetings may be requested exclusively via Piper Sandler.

About Tarsius Pharma

Tarsius Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.

The company has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 879598.  

Investor Contact:
Chuck Padala
LifeSci Advisors 
917-741-7792
chuck@lifesciadvisors.com